Recent 8-K filings for NUTX

• April 30, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Nutex Health Q1 2026 net income $46.8M, diluted EPS $6.52, revenue $216.5M

  Revenue $216.5M (+2.2% YoY); hospital division revenue $207.6M.

• April 23, 2026, 7:59 PM ET other materiality 0.10 neutral item 5.07

  Nutex Health annual meeting elects all 7 directors, approves say-on-pay and auditor ratification

  All seven director nominees elected; Thomas T. Vo received 2,554,009 votes 'for' and 89,198 withheld.

• March 5, 2026, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Nutex Health FY2025 revenue up 82% to $875M, diluted EPS $10.48; announces $25M buyback

  FY2025 total revenue $875.3M, up 82.4% YoY; net income $70.8M vs $52.1M; diluted EPS $10.48 vs $9.69.

• November 24, 2025, 6:59 PM ET other material materiality 0.10 neutral item 8.01item 9.01

  Nutex Health files auditor consent to incorporate 2023 audit report by reference

  Marcum LLP consent to incorporate Dec 31, 2023 audit report into registration statements.

• November 19, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Nutex Health Q3 2025 revenue $267.8M (+240% YoY), net income $55.4M vs loss $8.8M

  Total revenue $267.8M for Q3 2025, up 240% YoY; hospital division revenue $260.2M, up 263% YoY.

• November 18, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Nutex Health restates 2024 results: revenue $479.9M (+93.8% YoY), net income $52.1M vs loss $45.8M

  Restated full-year 2024: revenue $479.9M (up 93.8% YoY); net income $52.1M vs net loss $45.8M in 2023.

• November 18, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Nutex Health restates Q1 2025: revenue $211.8M, net income $21.2M, diluted EPS $3.33

  Total revenue $211.8M, up 214% YoY from $67.5M.

• November 18, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Nutex Health H1 2025 revenue $455.8M (+217.5% YoY), net income $3.5M, launches $25M buyback

  H1 2025 revenue $455.8M (+217.5% YoY); net income $3.5M vs net loss $0.7M in H1 2024.

• October 20, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 3.01item 9.01 ◈ Listing & Compliance Notices ×2

  Nutex Health Q3 prelim: cash collections up 259% YoY, patient volume +11.1%; Nasdaq extension granted

  Preliminary Q3 2025 patient volume of 46,293 visits, up 11.1% vs Q3 2024.

• September 22, 2025, 7:59 PM ET leadership materiality 0.60 neutral item 5.02item 7.01item 9.01

  Nutex Health appoints Wesley Bamburg as COO effective Oct 13, 2025

  Wesley Bamburg, former COO at HCA Houston Healthcare North Cypress, appointed COO effective October 13, 2025.

• September 10, 2025, 7:59 PM ET litigation materiality 0.60 negative item 8.01

  Derivative lawsuit filed against Nutex Health executives and board alleging violations and mismanagement

  Plaintiff Juan Camilo Jimenez filed derivative action in S.D. Texas (Case 4:25-cv-04253) on Sept 8, 2025.

• September 4, 2025, 7:59 PM ET leadership materiality 0.30 neutral item 5.02

  Nutex Health appoints Michael L. Reed as Lead Independent Director

  Michael L. Reed appointed Lead Independent Director effective Sept 2, 2025.

• August 25, 2025, 7:59 PM ET litigation materiality 0.75 negative item 8.01

  Securities class action lawsuit filed against Nutex Health tracking short seller report

  Putative class action filed Aug 22, 2025 in SD Texas (Case 4:25-cv-03999) claiming Sections 10(b) and 20(a) violations.

• August 21, 2025, 7:59 PM ET other material materiality 0.85 negative item 2.02item 3.01item 4.02item 8.01item 9.01 ◈ Auditor Changes◈ Listing & Compliance Notices

  Nutex Health restates FY2024 and Q1 2025; receives Nasdaq delisting notice for late filing

  Restatement due to misclassification of obligations for under-construction hospitals; liabilities increase $10-20M (Dec 2024) and $20-50M (Mar 2025); equity decreases correspondingly.

• August 14, 2025, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Nutex Health reports Q2 prelim revenue $244M (+221% YoY); announces $25M buyback, delays 10-Q

  Q2 2025 total revenue $244.0M, up 220.7% from $76.1M in Q2 2024; gross profit $124.9M (51.2% margin) vs $22.6M (29.7%).

• July 16, 2025, 7:59 PM ET other material materiality 0.15 neutral item 5.07

  Nutex Health shareholders approve director elections, equity plan amendment at annual meeting

  All seven director nominees elected; top vote-getter Frank Jaumot with 2,798,958 for, lowest Michael Reed with 2,253,524 for.

• July 11, 2025, 7:59 PM ET leadership materiality 0.60 neutral item 5.02item 9.01

  Nutex Health COO Joshua DeTillio resigns effective Aug 8, 2025 to become CEO elsewhere

  Joshua DeTillio notified Nutex Health of his resignation as COO effective August 8, 2025.

• May 21, 2025, 7:59 PM ET other materiality 0.65 negative item 4.01item 9.01

  Nutex Health dismisses CBIZ as auditor, appoints Grant Thornton; material weaknesses cited

  Audit committee dismissed CBIZ CPAs P.C. effective May 15, 2025; CBIZ did not issue an audit report.

• May 13, 2025, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Nutex Health Q1 revenue surges 214% to $211.8M; net income $14.6M vs loss $0.4M

  Diluted EPS $2.56 vs ($0.08) in Q1 2024; EBITDA $43.1M (+507% YoY).

• April 25, 2025, 7:59 PM ET other material materiality 0.65 negative item 4.01item 9.01

  Auditor Marcum LLP resigns; Nutex Health discloses material weaknesses, hires CBIZ

  Marcum LLP resigned as auditor on April 25, 2025, due to acquisition by CBIZ CPAs P.C.

• March 31, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Nutex Health reports FY 2024 net income of $52.2M vs loss of $45.8M in 2023; revenue up 93.8% to $479.9M

  FY 2024 total revenue $479.9M (+93.8% YoY); net income $52.2M vs net loss $45.8M in 2023.

• February 6, 2025, 6:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  Nutex Health reports >80% arbitration success rate in Q4 2024 under No Surprises Act

  Since July 2024, Nutex submits 60-70% of billable visits to arbitration monthly.

• November 7, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Nutex Health Q3: Revenue $78.8M (+26%), Adj EBITDA $13.5M (+938%), Operating income positive

  Q3 total revenue $78.8M vs $62.7M YoY (+26%); mature hospitals grew 20.7%.

• August 8, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Nutex Health Q2 revenue up 29% to $76.1M; Adjusted EBITDA up 200% to $12.0M

  Net loss attributable to Nutex of $0.4M vs $3.5M loss in Q2 2023; H1 net loss $0.7M vs $8.6M.

• July 25, 2024, 7:59 PM ET regulatory materiality 0.65 positive item 8.01item 9.01

  Nutex Health regains Nasdaq minimum bid price compliance after reverse stock split

  Received compliance notice from Nasdaq on July 24, 2024.

• July 5, 2024, 7:59 PM ET other material materiality 0.75 negative item 3.03item 5.03item 9.01

  Nutex Health effects 1-for-10 reverse stock split effective July 2, 2024

  Board approved 1-for-10 reverse stock split; filed July 1, effective 11:59 pm ET July 2, 2024.

• June 18, 2024, 7:59 PM ET regulatory materiality 0.75 negative item 3.01item 5.07item 9.01

  Nutex Health receives Nasdaq exception until July 22 to effect reverse stock split and regain $1 bid price

  Nasdaq Hearings Panel granted Nutex exception until July 22, 2024 to execute reverse split and regain $1.00 minimum bid.

• May 24, 2024, 7:59 PM ET regulatory materiality 0.85 negative item 3.01

  Nutex Health receives Nasdaq delisting notice for bid price non-compliance; appeals, hearing July 9

  Nasdaq notified Nutex that it failed to regain the $1.00 minimum bid price by May 20, 2024.

• May 9, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01 ◈ Earnings Releases

  Nutex Health Q1 2024 revenue $67.5M (+20% YoY); net loss narrows to $0.4M

  Revenue $67.5M vs $56.3M YoY; hospital visits up 21.1% to 40,068.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.75 · Most common event earnings

13 positive 8 negative 8 neutral

source · NUTX on sec.gov